Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine

被引:87
作者
Goff, DC
Hennen, J
Lyoo, IK
Tsai, G
Wald, LL
Evins, AE
Yurgelun-Todd, DA
Renshaw, PF
机构
[1] Massachusetts Gen Hosp, Schizophrenia Program, Boston, MA 02114 USA
[2] McLean Hosp, Brain Imaging Ctr, Boston, MA USA
[3] Harvard Univ, Sch Med, Consolidated Dept Psychiat, Boston, MA 02115 USA
关键词
schizophrenia; negative symptoms; glutamate; olanzapine; clozapine; spectroscopy;
D O I
10.1016/S0006-3223(01)01321-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Recent evidence suggests that effects upon glutamatergic transmission may contribute to the therapeutic action of certain atypical antipsychotic agents. Methods: Glutamate concentrations were measured in serum and were estimated (Glx/Cr) in cingulate cortex by proton magnetic resonance spectroscopy (MRS) in schizophrenia patients while they were being treated with conventional neuroleptics and then 8 weeks after switching to olanzapine. Serum glutamate concentrations were obtained from 11 subjects, and MRS estimates of Glx/Cr were available from 10 subjects at both time points. Results: Serum glutamate concentrations significantly increased after the switch from conventional agents to olanzapine; brain glutamate (Glx/Cr) did not change significantly; however, brain glutamate (Glx/Cr) concentrations increased significantly in patients who exhibited an improvement in negative symptoms with olanzapine compared with patients with no change or worsening of negative symptoms. Conclusions: Comparisons performed following the switch tom conventional agents to olanzapine are consistent with previous studies of clozapine and provide additional preliminary evidence supporting the hypothesis that effects on excitatory amino acid activity may contribute to olanzapine's efficacy for treating negative symptoms. (C) 2002 Society of Biological Psychiatry.
引用
收藏
页码:493 / 497
页数:5
相关论文
共 23 条
[1]  
Bartha R, 1997, ARCH GEN PSYCHIAT, V54, P959
[2]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[3]  
BENES FM, 1991, ARCH GEN PSYCHIAT, V48, P996
[4]   INCREASED DENSITY OF GLUTAMATE-IMMUNOREACTIVE VERTICAL PROCESSES IN SUPERFICIAL LAMINAE IN CINGULATE CORTEX OF SCHIZOPHRENIC BRAIN [J].
BENES, FM ;
SORENSEN, I ;
VINCENT, SL ;
BIRD, ED ;
SATHI, M .
CEREBRAL CORTEX, 1992, 2 (06) :503-512
[5]   Olanzapine: a basic science update [J].
Bymaster, F ;
Perry, KW ;
Nelson, DL ;
Wong, DT ;
Rasmussen, K ;
Moore, NA ;
Calligaro, DO .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 :36-40
[6]   The nagging question of the function of N-acetylaspartylglutamate [J].
Coyle, JT .
NEUROBIOLOGY OF DISEASE, 1997, 4 (3-4) :231-238
[7]   Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia [J].
Ende, G ;
Braus, DF ;
Walter, S ;
Weber-Fahr, W ;
Soher, B ;
Maudsley, AA ;
Henn, FA .
SCHIZOPHRENIA RESEARCH, 2000, 41 (03) :389-395
[8]   METABOLISM AND ROLE OF GLUTAMATE IN MAMMALIAN BRAIN [J].
ERECINSKA, M ;
SILVER, IA .
PROGRESS IN NEUROBIOLOGY, 1990, 35 (04) :245-296
[9]   Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics [J].
Evins, AE ;
Amico, ET ;
Shih, V ;
Goff, DC .
JOURNAL OF NEURAL TRANSMISSION, 1997, 104 (6-7) :761-766
[10]   The emerging role of glutamate in the pathophysiology and treatment of schizophrenia [J].
Goff, DC ;
Coyle, JT .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (09) :1367-1377